Celgene — Merger or Acquisition (January 2019)
26 slides from Celgene's merger presentation, Jan 3, 2019
Slide 1: Creating a Global BioPharma Leader
Creating a Global BioPharma Leader INVESTOR PRESENTATIONJANUARY 2019
Slide 2: Important information and where to find it
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectus equivalent document. No offering of securities shall be made except by means of a prospectus meet
Slide 3: Forward-looking statements
This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can generally identify forward-looking statements by the use of forward-looking terminology such
Slide 4: Creating a Global BioPharma Leader
Creating a Global BioPharma Leader INVESTOR PRESENTATIONJANUARY 2019
Slide 5: Our Strategic Foundation: Diversified Specialty BioPharma
Diversified Specialty BioPharma Best of BIOTECH Best of PHARMA INNOVATION Focused and Integrated The Best PEOPLE helping patients in their fight against serious disease Our Strategic Foundation
Slide 6: Creating a Leading Focused Biopharma Company
Creating a Leading Focused Biopharma Company Oncology: IO / Solid Tumors& Hematology Cardiovascular 10PHASE III ASSETS LEADING FRANCHISES Led by Opdivo and Yervoy as well as Revlimid and Pomalyst ROBUST EARLY- AND MID-STAGE PIPELINE(PHASE I / II ASSETS) 21ONCOLOGY: IO / Solid Tumors DEEP AND BROAD L
Slide 7: A Compelling Transaction
A Compelling Transaction $50 cash and 1.0 share of combined company (fixed exchange ratio) per Celgene shareTotal value of $102.43 per Celgene share based on Bristol-Myers Squibb’s closing stock price on 1/2/2019; total transaction value of approx. $90 billion (excluding CVR)$9.00 CVR upon FDA appro
Slide 8: Bristol-Myers Squibb Strategic Priorities and Approach to Business Development
Bristol-Myers Squibb Strategic Priorities and Approach to Business Development Strategically Aligned with Therapeutic Focus Compelling Science with Potential for Transformational Medicine Creates Value for Shareholders
Slide 9: The Right Transaction for Celgene
Two companies with one mission – discover, develop and deliver the most innovative medicines to patients with unmet medical needs across the continuum of careRecognizes and unlocks significant value for Celgene shareholders Delivers immediate and substantial cash valueProvides meaningful participati
Slide 10: Balanced and Leading Commercial Portfolio
Balanced and Leading Commercial Portfolio Oncology: Hematology Oncology: IO/Solid Tumors Immunology & Inflammation Cardiovascular Estimated Market Size (1) ($Bn) 9/30/18 LTM Revenues% of Total $8.6Bn ~23% $14.4Bn ~39% $6.1Bn ~17% $4.2Bn ~11% (1) Source: Market size projections are for 2022 from Eval
Slide 11: The Leading Oncology Company
The Leading Oncology CompanySelect Current Indications Innovative assets addressing Solid Tumors and Hematologic Malignancies Lymphomas Myeloid Diseases Multiple Myeloma RCC HCC H&N NSCLC Melanoma CML Hematology IO / Solid Tumors
Slide 12: Strong IO Business With Meaningful Growth Opportunities
Strong IO Business With Meaningful Growth Opportunities >50Tumors with Ongoing Trials >350Clinical Trials with BMS IO Agents 15+New IO Compounds in Development Strong Commercial Execution Annualized sales* * Last 12 months as of Q3, 2018 Advancing the Science in IO 20+Near Term Data Readouts $7.5B G
Slide 13: Positioned for Long Term Leadership in Hematology
Positioned for Long Term Leadership in Hematology CelMOD® Next wave beyond today’s IMiDs CAR-T Several potential best-in-class agents BCMA Multiple modalities(CAR-T, TCE, ADC) Platforms for Sustained Leadership and Growth High Value Near-Term Assets luspatercept liso-cel (JCAR017) bb2121 fedratinib
Slide 14: Revlimid IP Timeline
Earliest Forecasted Trial Decision 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 REMSOct 2020 PolymorphApr 2027 MDS MOUApr 11, 2023MCL MOUMay 15, 2023MM MOUOct 7, 2023 PolymorphNov 2024 MCL MOUJul 2028 Earliest Forecasted Appeal Decision Volume-Limited Natco Sales Permitted* COMOct 2019 LITIGATI
Slide 15: Strengthens Position in Immunology & Inflammation
Strengthens Position in Immunology & Inflammation Expanded Early Portfolio High Value Near-Term Assets ozanimod TYK2 Current Marketed Products U.S. NDA and EU MAA submissions planned for Q1 2019Potential for indication expansion beyond multiple sclerosis in IBD with Phase III trials ongoing in UC an
Slide 16: Six Near-Term Product Launch Opportunities
Six Near-Term Product Launch Opportunities with Potential for Greater than $15B in Revenue U.S. and EU regulatory submissions expected in first half 2019 in 2L MDS and Beta-Thalassemia CD19 CAR-T with strong efficacy and a potentially differentiated safety and tolerability profile for R/R DLBCL Pote
Slide 17: Deep and Broad Combined Pipeline
Deep and Broad Combined Pipeline Oncology: IO/Solid Tumors Relatlimab (anti-LAG3) Luspatercept (activin receptor fusion protein) Ozanimod (S1P1 modulator) CC-486 (DNA methylase inhibitor) Fedratinib (JAK2 inhibitor) Cabiralizumab (anti-CSF1R) Marizomib (proteasome inhibitor) TYK2 Inhibitor Nitroxyl
Slide 18: High Potential Agents and Pipeline Assets to Watch
High Potential Agents and Pipeline Assets to Watch JCARH125 (BCMA CAR T) CAR-T focused on R/R MMEstimated pivotal study in 2019 CC-92480 (CELMoD) R/R Multiple MyelomaEstimated pivotal study in 2019 CC-93269 (BCMA TCE) R/R Multiple MyelomaEstimated pivotal study in 2019 CSF1R Randomized Phase II stud
Slide 19: Leading Science and Innovative Platforms
Leading Science and Innovative Platforms Clinical Collaborations World-Class Chemistry Biologics and Synthetic Biologics Protein Homeostasis Immunomodulatory Agents Cell Therapies Epigenetics R&D Ecosystem Tumor Biology and Resistance
Slide 20: A Compelling Transaction
A Compelling Transaction $50 cash and 1.0 share of combined company (fixed exchange ratio) per Celgene shareTotal value of $102.43 per Celgene share based on Bristol-Myers Squibb’s closing stock price on 1/2/2019; total transaction value of approx. $90 billion (excluding CVR)$9.00 CVR upon FDA appro
Slide 21: Significant Financial Benefits to Shareholders
Significant Financial Benefits to Shareholders Transaction internal rate of return well in excess of Celgene and BMS cost of capital Combination will be more than 40% accretive to BMS standalone EPS in first full year >$45 billion in free cash flow generation over first three years of combination Co
Slide 22: ~$2.5 Billion of Synergies an Important Source of Value
~$2.5 Billion of Synergies an Important Source of Value ~55% ~35% ~10% SG&A R&D Manufacturing Commercial efficienciesCentral support functionsGeographic optimization Optimize research & early-stage portfolioReduce overlapping resources Leverage Bristol Biologics footprintOperational procurement effi
Slide 23: Strong Balance Sheet With Robust Cash Flow Generation
Strong Balance Sheet With Robust Cash Flow Generation $33.5B fully underwritten bridge facility obtained from Morgan Stanley and MUFGCommitted to and expect strong investment grade credit ratings for the combinationIntend to execute a ~$5B accelerated share repurchase program after transaction close
Slide 24: Clear Path to Close
Transaction expected to close in Q3 2019 Subject to approval of BMS and Celgene shareholders Regulatory approvals in a number of jurisdictions including U.S. and ECOther customary closing conditions Clear Path to Close
Slide 25: Creating a Leading Focused Biopharma Company
Creating a Leading Focused Biopharma Company Oncology: IO / Solid Tumors& Hematology Cardiovascular 10PHASE III ASSETS LEADING FRANCHISES Led by Opdivo and Yervoy as well as Revlimid and Pomalyst ROBUST EARLY- AND MID-STAGE PIPELINE(PHASE I / II ASSETS) 21ONCOLOGY: IO / Solid Tumors DEEP AND BROAD L
Slide 26: Q&A
Q&A